Rucaparib cost and price in India, used for ovarian cancer

Rucaparib 300mg is an anticancer medicine that is used to treat certain types of ovarian cancer and prostate cancer that begin in the female reproductive organs where eggs are formed, the fallopian tube that transports eggs released by the ovaries to the uterus, and the primary peritoneal layer of tissue that lines the abdomen.

The cancer is recurrent in adults who have completely or partially responded to other chemotherapy treatments. It also aids in the treatment of certain types of cancer, such as ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, in people who have a specific gene and have received at least two other chemotherapy treatments.

Rucaparib 300mg is also used to treat various types of prostate cancer that have spread to other parts of the body in people who have a specific gene and have had previous treatments. Rucaparib belongs to the poly (ADP-ribose) polymerase (PARP) inhibitor class of drugs. It works by killing cancer cells.

Rucaparib 300mg comes in the form of a tablet. Take this medication exactly as your doctor has advised you. Consume everything at once. It should not be chewed, crushed, or broken. It is usually taken twice daily, 12 hours apart, with or without food. Your doctor may need to delay your treatment or adjust the rucaparib dose as per your response to treatment and any side effects.

Consult with your doctor if you feel the same way. Your doctor will help you reduce or prevent this. Do not stop taking this medicine unless your doctor tells you to. Do not take a second dose of rucaparib if you vomit after taking it. Maintain your usual dosing schedule and consult with your doctor.

References:

1. Clovis Oncology Ireland Ltd, Electronic medicines compendium (emc), [Revised on Jan 2021] [ Accessed on 19th August 2021], https://www.medicines.org.uk/emc/files/pil.10027.pdf
2. Clovis Oncology, Inc, US Food and Drug Administration, [Revised on April 2018] [ Accessed on 19th August 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf
3. Prof Robert L Coleman et al; Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial; Lancet; Published on 28/10/2017; Accessed on 19/08/2021; https://pubmed.ncbi.nlm.nih.gov/28916367/

Rucaparib Uses

• Ovarian cancer
• Prostate cancer

Prostate cancer

Adults with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have previously received androgen receptor-directed therapy and taxane-based chemotherapy are eligible for treatment. Continue treatment until the disease worsens or the toxicity becomes intolerable. Should have had a gonadotropin-releasing hormone (GnRH) analogue or bilateral orchiectomy at the same time.

Ovarian cancer

Side effects of Rucaparib tablet

• Nausea
• Vomiting
• Constipation
• Diarrhea
• Stomach pain
• Loss of appetite
• Bas taste in the mouth
• Itching
• Mouth sores
• Nasal congestion
• Runny nose
• Sneezing
• Sore or scratchy throat
• Cough

If you found some serious side-effects of rucaparib like weakness, tiredness, fever, weight loss, easy bruising or bleeding, or blood in urine or stool, pale skin, shortness of breath, and rash.

• Indicated for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded completely or partially to platinum-based chemotherapy.
• 600 mg PO BID
• Continue until the disease progresses or the toxicity becomes intolerable.

Rucaparib brands in India